Price Alert: Shares of Chromadex (CDXC) Trade 12.37% Higher at Midday June 23

Equities Staff  |

Chromadex Corp (NASDAQ: CDXC) shares are up 12.37%, or $0.24 per share, as on 11:50:40 est today. After Opening the Day at $2.06, 612,396 shares of Chromadex have traded hands and the stock has moved between $2.28 and $2.05.  

This year the company has moved YTD 48.13%.

Chromadex anticipates its next earnings on 2022-08-02.

For technical charts, analysis, and more on Chromadex visit the company profile.

About Chromadex Corp

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®.

To get more information on Chromadex Corp and to follow the company's latest updates, you can visit the company's profile page here: Chromadex Corp's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content